Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Ivan de Kouchkovsky (ucsf)

Description

Summary

This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.

Official Title

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) As a Response Monitoring Tool in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

Details

Keywords

High Risk Prostate Carcinoma, Prostate Cancer, Prostatic Neoplasms, Prednisone, Abiraterone Acetate, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)

Eligibility

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ivan de Kouchkovsky, MD
ID
NCT06384222
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 32 study participants
Last Updated